Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | MB | P02144 | 1/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.59 |
| ▸ | CA3 | P07451 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | RARG | P13631 | 1/20 | 0.59 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL840360 | 0.86 | AOC3 (0.55) | SMN1; SMN2HTTL3MBTL1TSHRKMT2A | |
| SCHEMBL29622963 | 0.84 | AOC3 (0.67) | SMN1; SMN2HTTL3MBTL1TSHRKMT2A | |
| SCHEMBL274924 | 0.84 | TSHR (0.79) | SMN1; SMN2HTTL3MBTL1TSHRKMT2A | |
| SCHEMBL29622962 | 0.84 | AOC3 (0.67) | SMN1; SMN2HTTL3MBTL1TSHRKMT2A | |
| SCHEMBL861674 | 0.83 | SMN1; SMN2 (0.84) | SMN1; SMN2HTTL3MBTL1TSHRKMT2A | |
| SCHEMBL5541692 | 0.83 | POLB (0.53) | SMN1; SMN2HTTL3MBTL1TSHRKMT2A | |
| SCHEMBL7668834 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2HTTL3MBTL1TSHRKMT2A | |
| SCHEMBL1014074 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2HTTL3MBTL1TSHRKMT2A | |
| SCHEMBL155297 | 0.83 | RAB9A (0.64) | SMN1; SMN2HTTL3MBTL1TSHRKMT2A | |
| SCHEMBL95420 | 0.82 | SMN1; SMN2 (0.67) | SMN1; SMN2HTTL3MBTL1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117799197-A | Large-area electrochromic device and preparation method thereof | 绍兴百立盛新材料科技有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-101827838-A | Cannabinoid receptor ligand | ASTRAZENECA AB | 2010-09-08 | — | — | CN | claimed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | claimed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | claimed |
| US-5849746-A | Substituted 1,4-piperazine-heteroaryl derivatives as 5-HT1D receptor agonists | MERCK SHARP & DOHME LTD. (GB) | 1998-12-15 | — | — | US | claimed |
| CN-117799197-A | Large-area electrochromic device and preparation method thereof | 绍兴百立盛新材料科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2016128905-A1 | THIENOPYRROLE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-08-18 | — | — | WO | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-1493819-B1 | PROCESS FOR PRODUCING EITHER OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID AND OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID ESTER OR OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID AND OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID ESTER | UBE INDUSTRIES (JP) | 2014-11-12 | — | — | EP | disclosed |
| CN-101040053-B | Process for producing optically active (S or R) -beta-amino acid and optically active (R or S) -beta-amino acid ester, and beta-amino acid 2-alkoxyethyl ester and optically active (S or R) -beta-amino acid 2-alkoxyethyl ester | UBE INDUSTRIES | 2013-04-24 | — | — | CN | disclosed |
| CN-102994606-A | Process for production of optically active (S)- or (R)-beta-amino acids and optically active (R)- or (S)-beta -amino acid esters, and optically active (S)- or (R)-2-alkoxyethyl esters of beta-amino acids. | UBE INDUSTRIES | 2013-03-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| WO-1994022826-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-13 | — | — | WO | disclosed |
| US-5069991-A | NAPHTHOLACTAM OR ISINDOLENINE DYE | BASF AKTIENGESELLSCHAFT (DE) | 1991-12-03 | — | — | US | disclosed |
| EP-0364890-A2 | Panchromatic electrophotographical recording element | BASF Aktiengesellschaft (DE) | 1990-04-25 | — | — | EP | disclosed |
| EP-0318758-A2 | Multilayered electrophotographical recording material | BASF Aktiengesellschaft (DE) | 1989-06-07 | — | — | EP | disclosed |
| US-4755512-A | Pharmaceutically useful dihydropyridinyldicarboxylate amides and esters incorporating arylpiperazinylalkyl moities | BRISTOL-MYERS COMPANY (US) | 1988-07-05 | — | — | US | disclosed |
| US-4414213-A | CARDIOVASCULAR DISORDERS | MEAD JOHNSON & COMPANY (US) | 1983-11-08 | — | — | US | disclosed |
| US-3936462-A | CNS DEPRESSANT, ANALGESIC | STERLING DRUG INC. (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | SMN1; SMN2 2731/4885HTT 3069/4885L3MBTL1 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.